SK18322000A3 - Použitie molekuly nukleovej kyseliny, farmaceutický prostriedok s jej obsahom a molekula nukleovej kyseliny - Google Patents

Použitie molekuly nukleovej kyseliny, farmaceutický prostriedok s jej obsahom a molekula nukleovej kyseliny Download PDF

Info

Publication number: SK18322000A3
Authority: SK; Slovakia
Prior art keywords: nucleic acid; egr; acid molecule; sequence; seq
Prior art date: 1998-06-02

Application number

SK1832-2000A

Other languages

English (en)

Slovak (sk)

Inventor

Martin Braddock

Callum Jeffrey Campbell

Jean-Luc Schwachtgen

Original Assignee

Glaxo Group Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-06-02

Filing date

1999-06-02

Publication date

2001-11-06

1998-06-02 Priority claimed from GBGB9811836.7A external-priority patent/GB9811836D0/en

1998-07-11 Priority claimed from GBGB9815035.2A external-priority patent/GB9815035D0/en

1998-09-12 Priority claimed from GBGB9819846.8A external-priority patent/GB9819846D0/en

1998-12-23 Priority claimed from GBGB9828578.6A external-priority patent/GB9828578D0/en

1999-06-02 Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited

2001-11-06 Publication of SK18322000A3 publication Critical patent/SK18322000A3/sk

Links

150000007523 nucleic acids Chemical class 0.000 title claims abstract description 144
102000039446 nucleic acids Human genes 0.000 title claims abstract description 134
108020004707 nucleic acids Proteins 0.000 title claims abstract description 134
239000008194 pharmaceutical composition Substances 0.000 title claims description 11
101100444898 Mus musculus Egr1 gene Proteins 0.000 claims abstract description 239
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 151
102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 145
229920001184 polypeptide Polymers 0.000 claims abstract description 144
208000027418 Wounds and injury Diseases 0.000 claims abstract description 96
206010052428 Wound Diseases 0.000 claims abstract description 84
239000013598 vector Substances 0.000 claims abstract description 76
239000012634 fragment Substances 0.000 claims abstract description 74
241000282414 Homo sapiens Species 0.000 claims abstract description 37
108091023040 Transcription factor Proteins 0.000 claims abstract description 37
102000040945 Transcription factor Human genes 0.000 claims abstract description 37
238000011282 treatment Methods 0.000 claims abstract description 37
238000013518 transcription Methods 0.000 claims abstract description 34
230000035897 transcription Effects 0.000 claims abstract description 34
241000124008 Mammalia Species 0.000 claims abstract description 20
238000004519 manufacturing process Methods 0.000 claims abstract description 20
239000003814 drug Substances 0.000 claims abstract description 13
241000282412 Homo Species 0.000 claims abstract description 10
238000000034 method Methods 0.000 claims description 65
230000014509 gene expression Effects 0.000 claims description 64
230000027455 binding Effects 0.000 claims description 36
239000002245 particle Substances 0.000 claims description 31
238000006467 substitution reaction Methods 0.000 claims description 24
125000003729 nucleotide group Chemical group 0.000 claims description 23
239000002773 nucleotide Substances 0.000 claims description 22
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 21
239000010931 gold Substances 0.000 claims description 21
229910052737 gold Inorganic materials 0.000 claims description 21
108700025832 Serum Response Element Proteins 0.000 claims description 20
238000002560 therapeutic procedure Methods 0.000 claims description 20
238000012217 deletion Methods 0.000 claims description 19
230000037430 deletion Effects 0.000 claims description 19
230000033115 angiogenesis Effects 0.000 claims description 15
230000035876 healing Effects 0.000 claims description 14
101001049697 Homo sapiens Early growth response protein 1 Proteins 0.000 claims description 13
230000001105 regulatory effect Effects 0.000 claims description 13
239000000523 sample Substances 0.000 claims description 12
210000001519 tissue Anatomy 0.000 claims description 12
239000003937 drug carrier Substances 0.000 claims description 11
108091028043 Nucleic acid sequence Proteins 0.000 claims description 10
238000003780 insertion Methods 0.000 claims description 10
230000037431 insertion Effects 0.000 claims description 10
239000003795 chemical substances by application Substances 0.000 claims description 8
238000002360 preparation method Methods 0.000 claims description 8
230000002792 vascular Effects 0.000 claims description 7
206010012601 diabetes mellitus Diseases 0.000 claims description 6
201000004681 Psoriasis Diseases 0.000 claims description 5
238000010899 nucleation Methods 0.000 claims description 5
108700026226 TATA Box Proteins 0.000 claims description 4
238000007887 coronary angioplasty Methods 0.000 claims description 4
230000002980 postoperative effect Effects 0.000 claims description 4
231100000241 scar Toxicity 0.000 claims description 4
208000032544 Cicatrix Diseases 0.000 claims description 3
208000005764 Peripheral Arterial Disease Diseases 0.000 claims description 3
208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims description 3
230000037387 scars Effects 0.000 claims description 3
206010040943 Skin Ulcer Diseases 0.000 claims description 2
238000011069 regeneration method Methods 0.000 claims description 2
231100000019 skin ulcer Toxicity 0.000 claims description 2
230000001133 acceleration Effects 0.000 claims 1
230000010478 bone regeneration Effects 0.000 claims 1
230000010072 bone remodeling Effects 0.000 claims 1
239000003153 chemical reaction reagent Substances 0.000 claims 1
230000002708 enhancing effect Effects 0.000 claims 1
230000009395 genetic defect Effects 0.000 claims 1
229940124606 potential therapeutic agent Drugs 0.000 claims 1
238000010998 test method Methods 0.000 claims 1
230000033228 biological regulation Effects 0.000 abstract description 12
108010051542 Early Growth Response Protein 1 Proteins 0.000 abstract description 11
238000013461 design Methods 0.000 abstract description 3
102000040430 polynucleotide Human genes 0.000 description 106
108091033319 polynucleotide Proteins 0.000 description 106
239000002157 polynucleotide Substances 0.000 description 105
210000004027 cell Anatomy 0.000 description 102
108090000623 proteins and genes Proteins 0.000 description 48
238000001890 transfection Methods 0.000 description 37
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 34
230000000694 effects Effects 0.000 description 30
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 27
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 27
239000000203 mixture Substances 0.000 description 25
235000001014 amino acid Nutrition 0.000 description 23
108091032973 (ribonucleotides)n+m Proteins 0.000 description 22
230000029663 wound healing Effects 0.000 description 22
230000015572 biosynthetic process Effects 0.000 description 21
239000013612 plasmid Substances 0.000 description 21
102000004169 proteins and genes Human genes 0.000 description 20
241000701022 Cytomegalovirus Species 0.000 description 19
241000700159 Rattus Species 0.000 description 19
150000001413 amino acids Chemical class 0.000 description 19
238000005755 formation reaction Methods 0.000 description 19
235000018102 proteins Nutrition 0.000 description 19
108010005774 beta-Galactosidase Proteins 0.000 description 17
210000000988 bone and bone Anatomy 0.000 description 17
102100026189 Beta-galactosidase Human genes 0.000 description 16
125000003275 alpha amino acid group Chemical group 0.000 description 16
230000004048 modification Effects 0.000 description 16
238000012986 modification Methods 0.000 description 16
230000003938 response to stress Effects 0.000 description 16
239000013604 expression vector Substances 0.000 description 15
238000009396 hybridization Methods 0.000 description 15
230000004044 response Effects 0.000 description 15
101000817629 Homo sapiens Dymeclin Proteins 0.000 description 14
230000004913 activation Effects 0.000 description 14
239000003102 growth factor Substances 0.000 description 14
238000004458 analytical method Methods 0.000 description 13
150000001875 compounds Chemical class 0.000 description 13
230000006378 damage Effects 0.000 description 13
230000001965 increasing effect Effects 0.000 description 12
208000014674 injury Diseases 0.000 description 12
102000008186 Collagen Human genes 0.000 description 11
108010035532 Collagen Proteins 0.000 description 11
241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 11
108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 11
102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 11
229920001436 collagen Polymers 0.000 description 11
230000011164 ossification Effects 0.000 description 11
238000012360 testing method Methods 0.000 description 11
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 11
108091026890 Coding region Proteins 0.000 description 10
238000005516 engineering process Methods 0.000 description 10
238000011160 research Methods 0.000 description 10
210000000329 smooth muscle myocyte Anatomy 0.000 description 10
102000053602 DNA Human genes 0.000 description 9
239000002299 complementary DNA Substances 0.000 description 9
238000000338 in vitro Methods 0.000 description 9
150000002632 lipids Chemical class 0.000 description 9
230000028327 secretion Effects 0.000 description 9
210000003491 skin Anatomy 0.000 description 9
239000000243 solution Substances 0.000 description 9
108020004414 DNA Proteins 0.000 description 8
241001465754 Metazoa Species 0.000 description 8
210000000845 cartilage Anatomy 0.000 description 8
238000001415 gene therapy Methods 0.000 description 8
230000002068 genetic effect Effects 0.000 description 8
239000007943 implant Substances 0.000 description 8
238000001727 in vivo Methods 0.000 description 8
238000010186 staining Methods 0.000 description 8
230000001225 therapeutic effect Effects 0.000 description 8
102000002260 Alkaline Phosphatase Human genes 0.000 description 7
108020004774 Alkaline Phosphatase Proteins 0.000 description 7
108091003079 Bovine Serum Albumin Proteins 0.000 description 7
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 7
241000699666 Mus <mouse, genus> Species 0.000 description 7
238000007792 addition Methods 0.000 description 7
238000003501 co-culture Methods 0.000 description 7
230000008021 deposition Effects 0.000 description 7
230000003511 endothelial effect Effects 0.000 description 7
239000012894 fetal calf serum Substances 0.000 description 7
230000006870 function Effects 0.000 description 7
230000013595 glycosylation Effects 0.000 description 7
238000011065 in-situ storage Methods 0.000 description 7
108020004999 messenger RNA Proteins 0.000 description 7
238000010369 molecular cloning Methods 0.000 description 7
238000000746 purification Methods 0.000 description 7
230000000699 topical effect Effects 0.000 description 7
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
101100297347 Caenorhabditis elegans pgl-3 gene Proteins 0.000 description 6
241000588724 Escherichia coli Species 0.000 description 6
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
125000000539 amino acid group Chemical group 0.000 description 6
230000004071 biological effect Effects 0.000 description 6
239000000969 carrier Substances 0.000 description 6
238000010367 cloning Methods 0.000 description 6
239000006071 cream Substances 0.000 description 6
238000002474 experimental method Methods 0.000 description 6
238000006206 glycosylation reaction Methods 0.000 description 6
238000003384 imaging method Methods 0.000 description 6
230000035772 mutation Effects 0.000 description 6
239000008188 pellet Substances 0.000 description 6
239000000126 substance Substances 0.000 description 6
230000014616 translation Effects 0.000 description 6
210000005239 tubule Anatomy 0.000 description 6
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 6
108060001084 Luciferase Proteins 0.000 description 5
239000005089 Luciferase Substances 0.000 description 5
AXDLCFOOGCNDST-UHFFFAOYSA-N N-methyl-DL-tyrosine Natural products CNC(C(O)=O)CC1=CC=C(O)C=C1 AXDLCFOOGCNDST-UHFFFAOYSA-N 0.000 description 5
108091034117 Oligonucleotide Proteins 0.000 description 5
108091027981 Response element Proteins 0.000 description 5
241000283984 Rodentia Species 0.000 description 5
102000004446 Serum Response Factor Human genes 0.000 description 5
108010042291 Serum Response Factor Proteins 0.000 description 5
102000004887 Transforming Growth Factor beta Human genes 0.000 description 5
108090001012 Transforming Growth Factor beta Proteins 0.000 description 5
241000700605 Viruses Species 0.000 description 5
238000004113 cell culture Methods 0.000 description 5
230000000295 complement effect Effects 0.000 description 5
238000001514 detection method Methods 0.000 description 5
239000013613 expression plasmid Substances 0.000 description 5
108020001507 fusion proteins Proteins 0.000 description 5
102000037865 fusion proteins Human genes 0.000 description 5
238000012744 immunostaining Methods 0.000 description 5
230000001939 inductive effect Effects 0.000 description 5
238000002955 isolation Methods 0.000 description 5
239000011159 matrix material Substances 0.000 description 5
239000013642 negative control Substances 0.000 description 5
239000002674 ointment Substances 0.000 description 5
238000005457 optimization Methods 0.000 description 5
238000000053 physical method Methods 0.000 description 5
108010017843 platelet-derived growth factor A Proteins 0.000 description 5
230000008488 polyadenylation Effects 0.000 description 5
239000013641 positive control Substances 0.000 description 5
230000004481 post-translational protein modification Effects 0.000 description 5
238000012545 processing Methods 0.000 description 5
238000011084 recovery Methods 0.000 description 5
230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 5
230000035882 stress Effects 0.000 description 5
239000000758 substrate Substances 0.000 description 5
FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 5
229960005314 suramin Drugs 0.000 description 5
238000003786 synthesis reaction Methods 0.000 description 5
-1 terminal amino acids Chemical class 0.000 description 5
238000013519 translation Methods 0.000 description 5
238000011144 upstream manufacturing Methods 0.000 description 5
230000003612 virological effect Effects 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
208000004434 Calcinosis Diseases 0.000 description 4
108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 4
108020004705 Codon Proteins 0.000 description 4
102400001368 Epidermal growth factor Human genes 0.000 description 4
101800003838 Epidermal growth factor Proteins 0.000 description 4
102000003974 Fibroblast growth factor 2 Human genes 0.000 description 4
108090000379 Fibroblast growth factor 2 Proteins 0.000 description 4
ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 4
101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 description 4
101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 4
101000868152 Homo sapiens Son of sevenless homolog 1 Proteins 0.000 description 4
241000701024 Human betaherpesvirus 5 Species 0.000 description 4
229940124647 MEK inhibitor Drugs 0.000 description 4
241001529936 Murinae Species 0.000 description 4
108700026244 Open Reading Frames Proteins 0.000 description 4
240000004808 Saccharomyces cerevisiae Species 0.000 description 4
238000012300 Sequence Analysis Methods 0.000 description 4
108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
239000013543 active substance Substances 0.000 description 4
230000000692 anti-sense effect Effects 0.000 description 4
230000000903 blocking effect Effects 0.000 description 4
230000002308 calcification Effects 0.000 description 4
229940079593 drug Drugs 0.000 description 4
229940116977 epidermal growth factor Drugs 0.000 description 4
238000009472 formulation Methods 0.000 description 4
239000007789 gas Substances 0.000 description 4
230000012010 growth Effects 0.000 description 4
239000000463 material Substances 0.000 description 4
230000001404 mediated effect Effects 0.000 description 4
PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 4
230000008569 process Effects 0.000 description 4
238000003259 recombinant expression Methods 0.000 description 4
108091008146 restriction endonucleases Proteins 0.000 description 4
230000001177 retroviral effect Effects 0.000 description 4
239000004017 serum-free culture medium Substances 0.000 description 4
241000894007 species Species 0.000 description 4
239000006228 supernatant Substances 0.000 description 4
102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 3
238000002965 ELISA Methods 0.000 description 3
108700039691 Genetic Promoter Regions Proteins 0.000 description 3
241000238631 Hexapoda Species 0.000 description 3
101000762379 Homo sapiens Bone morphogenetic protein 4 Proteins 0.000 description 3
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
102000009151 Luteinizing Hormone Human genes 0.000 description 3
108010073521 Luteinizing Hormone Proteins 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
108010025020 Nerve Growth Factor Proteins 0.000 description 3
102000015336 Nerve Growth Factor Human genes 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
230000002491 angiogenic effect Effects 0.000 description 3
238000010171 animal model Methods 0.000 description 3
238000003556 assay Methods 0.000 description 3
230000001580 bacterial effect Effects 0.000 description 3
230000037396 body weight Effects 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
239000012228 culture supernatant Substances 0.000 description 3
125000004122 cyclic group Chemical group 0.000 description 3
230000007423 decrease Effects 0.000 description 3
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
239000006185 dispersion Substances 0.000 description 3
238000004520 electroporation Methods 0.000 description 3
108010030074 endodeoxyribonuclease MluI Proteins 0.000 description 3
230000004927 fusion Effects 0.000 description 3
230000001900 immune effect Effects 0.000 description 3
230000002055 immunohistochemical effect Effects 0.000 description 3
230000006698 induction Effects 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
239000000543 intermediate Substances 0.000 description 3
238000011068 loading method Methods 0.000 description 3
229940040129 luteinizing hormone Drugs 0.000 description 3
239000003550 marker Substances 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
229940053128 nerve growth factor Drugs 0.000 description 3
229910052757 nitrogen Inorganic materials 0.000 description 3
210000000963 osteoblast Anatomy 0.000 description 3
239000002953 phosphate buffered saline Substances 0.000 description 3
239000001267 polyvinylpyrrolidone Substances 0.000 description 3
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
238000001556 precipitation Methods 0.000 description 3
239000000047 product Substances 0.000 description 3
230000010076 replication Effects 0.000 description 3
230000036573 scar formation Effects 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
239000007858 starting material Substances 0.000 description 3
230000000638 stimulation Effects 0.000 description 3
229960005322 streptomycin Drugs 0.000 description 3
239000000725 suspension Substances 0.000 description 3
229940124597 therapeutic agent Drugs 0.000 description 3
230000005030 transcription termination Effects 0.000 description 3
230000002103 transcriptional effect Effects 0.000 description 3
230000003827 upregulation Effects 0.000 description 3
239000013603 viral vector Substances 0.000 description 3
238000001262 western blot Methods 0.000 description 3
DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 2
ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 2
201000004384 Alopecia Diseases 0.000 description 2
206010002091 Anaesthesia Diseases 0.000 description 2
101100489887 Arabidopsis thaliana ABA2 gene Proteins 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
108010081589 Becaplermin Proteins 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
208000006029 Cardiomegaly Diseases 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
102000012422 Collagen Type I Human genes 0.000 description 2
108010022452 Collagen Type I Proteins 0.000 description 2
230000004568 DNA-binding Effects 0.000 description 2
102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 description 2
101710146526 Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 description 2
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 2
108060006698 EGF receptor Proteins 0.000 description 2
238000012286 ELISA Assay Methods 0.000 description 2
102000003972 Fibroblast growth factor 7 Human genes 0.000 description 2
108090000385 Fibroblast growth factor 7 Proteins 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
108091092195 Intron Proteins 0.000 description 2
102000003792 Metallothionein Human genes 0.000 description 2
108090000157 Metallothionein Proteins 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 2
208000034827 Neointima Diseases 0.000 description 2
GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 2
108700020796 Oncogene Proteins 0.000 description 2
108091093037 Peptide nucleic acid Proteins 0.000 description 2
108020004511 Recombinant DNA Proteins 0.000 description 2
241000714474 Rous sarcoma virus Species 0.000 description 2
101100501251 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) ELO3 gene Proteins 0.000 description 2
108020004682 Single-Stranded DNA Proteins 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
108091081024 Start codon Proteins 0.000 description 2
108010000499 Thromboplastin Proteins 0.000 description 2
102000002262 Thromboplastin Human genes 0.000 description 2
108700009124 Transcription Initiation Site Proteins 0.000 description 2
208000025865 Ulcer Diseases 0.000 description 2
208000005475 Vascular calcification Diseases 0.000 description 2
208000008383 Wilms tumor Diseases 0.000 description 2
239000000654 additive Substances 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
238000001042 affinity chromatography Methods 0.000 description 2
230000037005 anaesthesia Effects 0.000 description 2
230000000890 antigenic effect Effects 0.000 description 2
238000013459 approach Methods 0.000 description 2
230000008901 benefit Effects 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
230000008827 biological function Effects 0.000 description 2
210000002449 bone cell Anatomy 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
239000007975 buffered saline Substances 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
239000011575 calcium Substances 0.000 description 2
230000004663 cell proliferation Effects 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
230000008859 change Effects 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
230000002759 chromosomal effect Effects 0.000 description 2
208000019425 cirrhosis of liver Diseases 0.000 description 2
238000003776 cleavage reaction Methods 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
230000008602 contraction Effects 0.000 description 2
238000004132 cross linking Methods 0.000 description 2
238000005520 cutting process Methods 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
230000007547 defect Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
239000008121 dextrose Substances 0.000 description 2
238000003745 diagnosis Methods 0.000 description 2
230000004069 differentiation Effects 0.000 description 2
SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
239000003221 ear drop Substances 0.000 description 2
229940047652 ear drops Drugs 0.000 description 2
239000003974 emollient agent Substances 0.000 description 2
210000002889 endothelial cell Anatomy 0.000 description 2
239000003623 enhancer Substances 0.000 description 2
238000000605 extraction Methods 0.000 description 2
239000003889 eye drop Substances 0.000 description 2
229940012356 eye drops Drugs 0.000 description 2
239000003885 eye ointment Substances 0.000 description 2
230000003176 fibrotic effect Effects 0.000 description 2
238000010304 firing Methods 0.000 description 2
238000004108 freeze drying Methods 0.000 description 2
238000007710 freezing Methods 0.000 description 2
230000008014 freezing Effects 0.000 description 2
239000003517 fume Substances 0.000 description 2
230000006251 gamma-carboxylation Effects 0.000 description 2
238000001476 gene delivery Methods 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
229960004198 guanidine Drugs 0.000 description 2
238000010191 image analysis Methods 0.000 description 2
238000003364 immunohistochemistry Methods 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
239000002502 liposome Substances 0.000 description 2
238000012423 maintenance Methods 0.000 description 2
210000004962 mammalian cell Anatomy 0.000 description 2
239000002324 mouth wash Substances 0.000 description 2
229940051866 mouthwash Drugs 0.000 description 2
238000002703 mutagenesis Methods 0.000 description 2
231100000350 mutagenesis Toxicity 0.000 description 2
230000008692 neointimal formation Effects 0.000 description 2
238000010606 normalization Methods 0.000 description 2
201000008968 osteosarcoma Diseases 0.000 description 2
238000002161 passivation Methods 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
239000002644 phorbol ester Substances 0.000 description 2
239000013600 plasmid vector Substances 0.000 description 2
238000007747 plating Methods 0.000 description 2
230000017363 positive regulation of growth Effects 0.000 description 2
239000002243 precursor Substances 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
230000001737 promoting effect Effects 0.000 description 2
238000011321 prophylaxis Methods 0.000 description 2
230000002797 proteolythic effect Effects 0.000 description 2
230000002685 pulmonary effect Effects 0.000 description 2
208000005069 pulmonary fibrosis Diseases 0.000 description 2
238000011002 quantification Methods 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
230000037425 regulation of transcription Effects 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
230000007017 scission Effects 0.000 description 2
238000012216 screening Methods 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
238000002864 sequence alignment Methods 0.000 description 2
239000011734 sodium Substances 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
210000004872 soft tissue Anatomy 0.000 description 2
239000002904 solvent Substances 0.000 description 2
238000009331 sowing Methods 0.000 description 2
ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
238000012453 sprague-dawley rat model Methods 0.000 description 2
101150036683 sre1 gene Proteins 0.000 description 2
238000003756 stirring Methods 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
230000017423 tissue regeneration Effects 0.000 description 2
238000012546 transfer Methods 0.000 description 2
230000009466 transformation Effects 0.000 description 2
231100000397 ulcer Toxicity 0.000 description 2
238000002604 ultrasonography Methods 0.000 description 2
241001515965 unidentified phage Species 0.000 description 2
230000006711 vascular endothelial growth factor production Effects 0.000 description 2
210000004509 vascular smooth muscle cell Anatomy 0.000 description 2
230000001457 vasomotor Effects 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
230000002861 ventricular Effects 0.000 description 2
108010047303 von Willebrand Factor Proteins 0.000 description 2
CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 description 1
RVCKCEDKBVEEHL-UHFFFAOYSA-N 2,3,4,5,6-pentachlorobenzyl alcohol Chemical compound OCC1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1Cl RVCKCEDKBVEEHL-UHFFFAOYSA-N 0.000 description 1
PIINGYXNCHTJTF-UHFFFAOYSA-N 2-(2-azaniumylethylamino)acetate Chemical compound NCCNCC(O)=O PIINGYXNCHTJTF-UHFFFAOYSA-N 0.000 description 1
KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 description 1
108020005029 5' Flanking Region Proteins 0.000 description 1
QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 1
230000005730 ADP ribosylation Effects 0.000 description 1
102000015936 AP-1 transcription factor Human genes 0.000 description 1
108050004195 AP-1 transcription factor Proteins 0.000 description 1
102400000345 Angiotensin-2 Human genes 0.000 description 1
101800000733 Angiotensin-2 Proteins 0.000 description 1
206010003162 Arterial injury Diseases 0.000 description 1
241000228212 Aspergillus Species 0.000 description 1
244000063299 Bacillus subtilis Species 0.000 description 1
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
208000005623 Carcinogenesis Diseases 0.000 description 1
206010007572 Cardiac hypertrophy Diseases 0.000 description 1
208000010867 Carotid Artery injury Diseases 0.000 description 1
208000002177 Cataract Diseases 0.000 description 1
IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
206010051055 Deep vein thrombosis Diseases 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
238000009007 Diagnostic Kit Methods 0.000 description 1
241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
102000001301 EGF receptor Human genes 0.000 description 1
101150114117 EGR1 gene Proteins 0.000 description 1
102100023226 Early growth response protein 1 Human genes 0.000 description 1
101150033452 Elk1 gene Proteins 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
241000701959 Escherichia virus Lambda Species 0.000 description 1
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
108010001515 Galectin 4 Proteins 0.000 description 1
102100039556 Galectin-4 Human genes 0.000 description 1
101000887160 Gallus gallus Gallinacin-14 Proteins 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
206010019280 Heart failures Diseases 0.000 description 1
102100021866 Hepatocyte growth factor Human genes 0.000 description 1
101000583053 Homo sapiens NGFI-A-binding protein 1 Proteins 0.000 description 1
101000583057 Homo sapiens NGFI-A-binding protein 2 Proteins 0.000 description 1
101000620620 Homo sapiens Placental protein 13-like Proteins 0.000 description 1
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
229930010555 Inosine Natural products 0.000 description 1
UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
238000012313 Kruskal-Wallis test Methods 0.000 description 1
229930182816 L-glutamine Natural products 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
102000043136 MAP kinase family Human genes 0.000 description 1
108091054455 MAP kinase family Proteins 0.000 description 1
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
101710167839 Morphogenetic protein Proteins 0.000 description 1
101000808007 Mus musculus Vascular endothelial growth factor A Proteins 0.000 description 1
CZSLEMCYYGEGKP-UHFFFAOYSA-N N-(2-chlorobenzyl)-1-(2,5-dimethylphenyl)benzimidazole-5-carboxamide Chemical compound CC1=CC=C(C)C(N2C3=CC=C(C=C3N=C2)C(=O)NCC=2C(=CC=CC=2)Cl)=C1 CZSLEMCYYGEGKP-UHFFFAOYSA-N 0.000 description 1
PYUSHNKNPOHWEZ-YFKPBYRVSA-N N-formyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC=O PYUSHNKNPOHWEZ-YFKPBYRVSA-N 0.000 description 1
102100030407 NGFI-A-binding protein 1 Human genes 0.000 description 1
102100030391 NGFI-A-binding protein 2 Human genes 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
108091005461 Nucleic proteins Proteins 0.000 description 1
102000015636 Oligopeptides Human genes 0.000 description 1
108010038807 Oligopeptides Proteins 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
208000001715 Osteoblastoma Diseases 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
102000003992 Peroxidases Human genes 0.000 description 1
102100022336 Placental protein 13-like Human genes 0.000 description 1
108010069381 Platelet Endothelial Cell Adhesion Molecule-1 Proteins 0.000 description 1
102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 1
208000004210 Pressure Ulcer Diseases 0.000 description 1
108010018070 Proto-Oncogene Proteins c-ets Proteins 0.000 description 1
102000004053 Proto-Oncogene Proteins c-ets Human genes 0.000 description 1
241000711798 Rabies lyssavirus Species 0.000 description 1
101100287693 Rattus norvegicus Kcnh4 gene Proteins 0.000 description 1
101100287705 Rattus norvegicus Kcnh8 gene Proteins 0.000 description 1
108700008625 Reporter Genes Proteins 0.000 description 1
AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
101100478321 Schizosaccharomyces pombe (strain 972 / ATCC 24843) sre2 gene Proteins 0.000 description 1
206010072170 Skin wound Diseases 0.000 description 1
108010053551 Sp1 Transcription Factor Proteins 0.000 description 1
241000256248 Spodoptera Species 0.000 description 1
241000295644 Staphylococcaceae Species 0.000 description 1
241000187747 Streptomyces Species 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
241000282887 Suidae Species 0.000 description 1
108020005038 Terminator Codon Proteins 0.000 description 1
102000006601 Thymidine Kinase Human genes 0.000 description 1
108020004440 Thymidine kinase Proteins 0.000 description 1
102100030246 Transcription factor Sp1 Human genes 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
241000700618 Vaccinia virus Species 0.000 description 1
206010046865 Vaccinia virus infection Diseases 0.000 description 1
241000700647 Variola virus Species 0.000 description 1
206010047249 Venous thrombosis Diseases 0.000 description 1
208000026448 Wilms tumor 1 Diseases 0.000 description 1
102000038627 Zinc finger transcription factors Human genes 0.000 description 1
108091007916 Zinc finger transcription factors Proteins 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
230000021736 acetylation Effects 0.000 description 1
238000006640 acetylation reaction Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000010933 acylation Effects 0.000 description 1
238000005917 acylation reaction Methods 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
230000032683 aging Effects 0.000 description 1
238000013019 agitation Methods 0.000 description 1
230000008484 agonism Effects 0.000 description 1
238000007605 air drying Methods 0.000 description 1
231100000360 alopecia Toxicity 0.000 description 1
230000009435 amidation Effects 0.000 description 1
238000007112 amidation reaction Methods 0.000 description 1
150000001408 amides Chemical group 0.000 description 1
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
229910052921 ammonium sulfate Inorganic materials 0.000 description 1
238000012870 ammonium sulfate precipitation Methods 0.000 description 1
235000011130 ammonium sulphate Nutrition 0.000 description 1
230000003321 amplification Effects 0.000 description 1
238000002399 angioplasty Methods 0.000 description 1
229950006323 angiotensin ii Drugs 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
238000005571 anion exchange chromatography Methods 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
230000010516 arginylation Effects 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
238000010876 biochemical test Methods 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
229960000074 biopharmaceutical Drugs 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
230000010256 bone deposition Effects 0.000 description 1
210000002805 bone matrix Anatomy 0.000 description 1
230000004097 bone metabolism Effects 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
230000036952 cancer formation Effects 0.000 description 1
235000011089 carbon dioxide Nutrition 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
231100000504 carcinogenesis Toxicity 0.000 description 1
230000005800 cardiovascular problem Effects 0.000 description 1
238000005277 cation exchange chromatography Methods 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
239000002771 cell marker Substances 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
230000002925 chemical effect Effects 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
230000003399 chemotactic effect Effects 0.000 description 1
210000000038 chest Anatomy 0.000 description 1
210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
201000002816 chronic venous insufficiency Diseases 0.000 description 1
ALSTYHKOOCGGFT-UHFFFAOYSA-N cis-oleyl alcohol Natural products CCCCCCCCC=CCCCCCCCCO ALSTYHKOOCGGFT-UHFFFAOYSA-N 0.000 description 1
238000007398 colorimetric assay Methods 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
230000000536 complexating effect Effects 0.000 description 1
238000004590 computer program Methods 0.000 description 1
238000010276 construction Methods 0.000 description 1
238000012937 correction Methods 0.000 description 1
239000000287 crude extract Substances 0.000 description 1
238000012258 culturing Methods 0.000 description 1
229940095074 cyclic amp Drugs 0.000 description 1
229960003067 cystine Drugs 0.000 description 1
230000000093 cytochemical effect Effects 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
235000015872 dietary supplement Nutrition 0.000 description 1
XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
229960002986 dinoprostone Drugs 0.000 description 1
238000009826 distribution Methods 0.000 description 1
230000003828 downregulation Effects 0.000 description 1
230000002500 effect on skin Effects 0.000 description 1
210000002472 endoplasmic reticulum Anatomy 0.000 description 1
210000003038 endothelium Anatomy 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
238000001952 enzyme assay Methods 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
229960001123 epoprostenol Drugs 0.000 description 1
235000004626 essential fatty acids Nutrition 0.000 description 1
238000012869 ethanol precipitation Methods 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
230000029142 excretion Effects 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
210000002744 extracellular matrix Anatomy 0.000 description 1
210000003414 extremity Anatomy 0.000 description 1
239000000835 fiber Substances 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
238000011049 filling Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
230000022244 formylation Effects 0.000 description 1
238000006170 formylation reaction Methods 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
238000007429 general method Methods 0.000 description 1
125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
229960000789 guanidine hydrochloride Drugs 0.000 description 1
PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
230000003676 hair loss Effects 0.000 description 1
BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
229960003132 halothane Drugs 0.000 description 1
230000000004 hemodynamic effect Effects 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
238000010562 histological examination Methods 0.000 description 1
230000006801 homologous recombination Effects 0.000 description 1
238000002744 homologous recombination Methods 0.000 description 1
102000053455 human SRE Human genes 0.000 description 1
108700023995 human SRE Proteins 0.000 description 1
102000043827 human Smooth muscle Human genes 0.000 description 1
108700038605 human Smooth muscle Proteins 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
210000002758 humerus Anatomy 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
238000012872 hydroxylapatite chromatography Methods 0.000 description 1
230000033444 hydroxylation Effects 0.000 description 1
238000005805 hydroxylation reaction Methods 0.000 description 1
230000001969 hypertrophic effect Effects 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
238000012151 immunohistochemical method Methods 0.000 description 1
238000002513 implantation Methods 0.000 description 1
230000001976 improved effect Effects 0.000 description 1
238000011534 incubation Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000013383 initial experiment Methods 0.000 description 1
229960003786 inosine Drugs 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
230000026045 iodination Effects 0.000 description 1
238000006192 iodination reaction Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
208000028867 ischemia Diseases 0.000 description 1
230000000302 ischemic effect Effects 0.000 description 1
238000011813 knockout mouse model Methods 0.000 description 1
101150109249 lacI gene Proteins 0.000 description 1
101150066555 lacZ gene Proteins 0.000 description 1
150000002617 leukotrienes Chemical class 0.000 description 1
210000003041 ligament Anatomy 0.000 description 1
239000003446 ligand Substances 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
230000002934 lysing effect Effects 0.000 description 1
238000007433 macroscopic evaluation Methods 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
239000002609 medium Substances 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
239000002184 metal Substances 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
230000011987 methylation Effects 0.000 description 1
238000007069 methylation reaction Methods 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
238000000520 microinjection Methods 0.000 description 1
239000011859 microparticle Substances 0.000 description 1
238000007431 microscopic evaluation Methods 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
210000005087 mononuclear cell Anatomy 0.000 description 1
125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
210000000107 myocyte Anatomy 0.000 description 1
230000007498 myristoylation Effects 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
201000001119 neuropathy Diseases 0.000 description 1
230000007823 neuropathy Effects 0.000 description 1
230000035771 neuroregeneration Effects 0.000 description 1
239000001272 nitrous oxide Substances 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
239000002777 nucleoside Substances 0.000 description 1
150000003833 nucleoside derivatives Chemical class 0.000 description 1
239000003883 ointment base Substances 0.000 description 1
229940055577 oleyl alcohol Drugs 0.000 description 1
XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
230000010258 osteoblastogenesis Effects 0.000 description 1
230000004819 osteoinduction Effects 0.000 description 1
230000001151 other effect Effects 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
206010033675 panniculitis Diseases 0.000 description 1
230000035515 penetration Effects 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
238000010647 peptide synthesis reaction Methods 0.000 description 1
208000033808 peripheral neuropathy Diseases 0.000 description 1
210000001322 periplasm Anatomy 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
230000002688 persistence Effects 0.000 description 1
229940080469 phosphocellulose Drugs 0.000 description 1
150000004713 phosphodiesters Chemical group 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
230000003169 placental effect Effects 0.000 description 1
229940127126 plasminogen activator Drugs 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000004033 plastic Substances 0.000 description 1
108010000685 platelet-derived growth factor AB Proteins 0.000 description 1
230000008092 positive effect Effects 0.000 description 1
230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
230000001323 posttranslational effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000013823 prenylation Effects 0.000 description 1
238000002203 pretreatment Methods 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
230000001023 pro-angiogenic effect Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
230000009145 protein modification Effects 0.000 description 1
230000030788 protein refolding Effects 0.000 description 1
238000001243 protein synthesis Methods 0.000 description 1
230000006340 racemization Effects 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
230000008439 repair process Effects 0.000 description 1
230000008458 response to injury Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
210000003705 ribosome Anatomy 0.000 description 1
238000011808 rodent model Methods 0.000 description 1
238000005070 sampling Methods 0.000 description 1
210000004116 schwann cell Anatomy 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
238000004904 shortening Methods 0.000 description 1
210000004927 skin cell Anatomy 0.000 description 1
210000003625 skull Anatomy 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
238000000527 sonication Methods 0.000 description 1
229940063673 spermidine Drugs 0.000 description 1
238000009987 spinning Methods 0.000 description 1
238000013222 sprague-dawley male rat Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
238000003860 storage Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
210000004304 subcutaneous tissue Anatomy 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
230000019635 sulfation Effects 0.000 description 1
238000005670 sulfation reaction Methods 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
230000008685 targeting Effects 0.000 description 1
210000002435 tendon Anatomy 0.000 description 1
238000010257 thawing Methods 0.000 description 1
230000001732 thrombotic effect Effects 0.000 description 1
210000002303 tibia Anatomy 0.000 description 1
239000003104 tissue culture media Substances 0.000 description 1
230000000451 tissue damage Effects 0.000 description 1
231100000827 tissue damage Toxicity 0.000 description 1
230000007838 tissue remodeling Effects 0.000 description 1
238000004448 titration Methods 0.000 description 1
229950003937 tolonium Drugs 0.000 description 1
HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
230000005026 transcription initiation Effects 0.000 description 1
238000010361 transduction Methods 0.000 description 1
230000026683 transduction Effects 0.000 description 1
238000003146 transient transfection Methods 0.000 description 1
230000014621 translational initiation Effects 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
238000010798 ubiquitination Methods 0.000 description 1
230000034512 ubiquitination Effects 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
241000701447 unidentified baculovirus Species 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
210000000689 upper leg Anatomy 0.000 description 1
208000007089 vaccinia Diseases 0.000 description 1
201000002282 venous insufficiency Diseases 0.000 description 1
238000003260 vortexing Methods 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Genetics & Genomics (AREA)
Chemical Kinetics & Catalysis (AREA)
Molecular Biology (AREA)
Toxicology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Marine Sciences & Fisheries (AREA)
Immunology (AREA)
Dermatology (AREA)
Biotechnology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Peptides Or Proteins (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

SK1832-2000A 1998-06-02 1999-06-02 Použitie molekuly nukleovej kyseliny, farmaceutický prostriedok s jej obsahom a molekula nukleovej kyseliny SK18322000A3 (sk)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
GBGB9811836.7A GB9811836D0 (en)	1998-06-02	1998-06-02	Gene therapy method
GBGB9815035.2A GB9815035D0 (en)	1998-07-11	1998-07-11	Gene therapy method
GBGB9819846.8A GB9819846D0 (en)	1998-09-12	1998-09-12	Gene therapy method
GBGB9828578.6A GB9828578D0 (en)	1998-12-23	1998-12-23	Regulation
PCT/GB1999/001722 WO1999062561A2 (en)	1998-06-02	1999-06-02	Gene therapy method

Publications (1)

Publication Number	Publication Date
SK18322000A3 true SK18322000A3 (sk)	2001-11-06

Family

ID=27451790

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1832-2000A SK18322000A3 (sk)	1998-06-02	1999-06-02	Použitie molekuly nukleovej kyseliny, farmaceutický prostriedok s jej obsahom a molekula nukleovej kyseliny

Country Status (28)

Country	Link
US (1)	US6689758B1 (de)
EP (2)	EP1281763A3 (de)
JP (1)	JP2002516676A (de)
KR (1)	KR20010043968A (de)
CN (1)	CN1311822A (de)
AP (1)	AP2000001999A0 (de)
AT (1)	ATE246518T1 (de)
AU (1)	AU770497B2 (de)
BR (1)	BR9910877A (de)
CA (1)	CA2334171A1 (de)
DE (1)	DE69910202T2 (de)
DK (1)	DK1083934T3 (de)
EA (1)	EA200001124A1 (de)
EE (1)	EE200000790A (de)
ES (1)	ES2205830T3 (de)
HR (1)	HRP20000832A2 (de)
HU (1)	HUP0103252A3 (de)
ID (1)	ID27483A (de)
IL (1)	IL139936A0 (de)
IS (1)	IS5742A (de)
NO (1)	NO20006047L (de)
NZ (1)	NZ508505A (de)
PL (1)	PL345207A1 (de)
PT (1)	PT1083934E (de)
SK (1)	SK18322000A3 (de)
TR (2)	TR200100348T2 (de)
WO (1)	WO1999062561A2 (de)
YU (1)	YU75600A (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9928430D0 (en) *	1999-12-01	2000-01-26	Glaxo Group Ltd	Screening
EP1467207B1 (de) *	2002-01-10	2008-06-04	Takeda Pharmaceutical Company Limited	Screening-verfahren für eine prophylaktische und therapeutische Substanz für eine Nierenerkrankung
WO2004060476A2 (en) *	2002-12-31	2004-07-22	The Johns Hopkins University	Wound healing method and kits
AU2004268457A1 (en) *	2003-08-29	2005-03-10	Anges Mg, Inc.	Gene therapy for skin disorders using needleless syringes
DE10342071B4 (de) *	2003-09-10	2006-01-19	Fleischmann, Wilhelm, Dr.med.	Vorrichtung und Verfahren zur Applikation von Wïrkstoffen an eine Wundoberfläche
KR100647490B1 (ko)	2004-10-04	2006-11-23	사회복지법인 삼성생명공익재단	저산소 조건 및 다른 스트레스에 특이적으로 반응할 수있는 키메라 인핸서 요소를 포함하는 벡터, 상기 벡터를포함하는 약제학적 조성물 및 상기 조성물을 이용하는 방법
CA2723672C (en)	2007-05-11	2019-09-03	Adynxx, Inc.	Gene expression and pain
FR2920158B1 (fr) *	2007-08-24	2010-03-12	Centre Nat Rech Scient	Production de plasmides et expression de proteines recombinantes dans des cellules cultivees sans antibiotiques
FR2924128A1 (fr) *	2007-11-26	2009-05-29	Galderma Res & Dev	Modulateurs de egr1 dans le traitement de l'alopecie
EP2454368A4 (de)	2009-07-17	2013-01-09	Aaron Thomas Tabor	Zusammensetzungen und verfahren zur genetischen modifizierung von zellen mit kosmetischer funktion zur verbesserung des kosmetischen erscheinungsbilds
CN102552938A (zh) *	2012-03-22	2012-07-11	南京大学	Egr-1拮抗剂在制备治疗Ⅱ型糖尿病的药物中的用途
EP3511022A1 (de)	2012-05-10	2019-07-17	Adynxx, Inc.	Formulierungen zur abgabe von wirkstoffen
JP6705807B2 (ja)	2014-08-15	2020-06-03	エーダイニクスインコーポレイテッド	疼痛を治療するためのオリゴヌクレオチドデコイ
KR101721228B1 (ko) *	2015-04-03	2017-03-30	사회복지법인 삼성생명공익재단	지방유래 줄기세포의 배양액을 유효성분으로 포함하는 발모촉진용 조성물
CN104857529A (zh) *	2015-05-20	2015-08-26	山西大学	Egr-1基因在制备抗膀胱癌药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5763209A (en)	1988-09-26	1998-06-09	Arch Development Corporation	Methods and materials relating to the functional domains of DNA binding proteins
US5206152A (en)	1988-04-08	1993-04-27	Arch Development Corporation	Cloning and expression of early growth regulatory protein genes
AUPN855496A0 (en)	1996-03-07	1996-04-04	Unisearch Limited	Prevention of proliferation of vascular cells

1999
- 1999-06-02 DE DE69910202T patent/DE69910202T2/de not_active Expired - Fee Related
- 1999-06-02 PT PT99925174T patent/PT1083934E/pt unknown
- 1999-06-02 AT AT99925174T patent/ATE246518T1/de not_active IP Right Cessation
- 1999-06-02 ID IDW20002711A patent/ID27483A/id unknown
- 1999-06-02 ES ES99925174T patent/ES2205830T3/es not_active Expired - Lifetime
- 1999-06-02 KR KR1020007013584A patent/KR20010043968A/ko not_active Withdrawn
- 1999-06-02 WO PCT/GB1999/001722 patent/WO1999062561A2/en not_active Ceased
- 1999-06-02 SK SK1832-2000A patent/SK18322000A3/sk unknown
- 1999-06-02 AP APAP/P/2000/001999A patent/AP2000001999A0/en unknown
- 1999-06-02 NZ NZ508505A patent/NZ508505A/xx unknown
- 1999-06-02 PL PL99345207A patent/PL345207A1/xx not_active Application Discontinuation
- 1999-06-02 EP EP02020179A patent/EP1281763A3/de not_active Withdrawn
- 1999-06-02 EA EA200001124A patent/EA200001124A1/ru unknown
- 1999-06-02 EP EP99925174A patent/EP1083934B1/de not_active Expired - Lifetime
- 1999-06-02 US US09/701,749 patent/US6689758B1/en not_active Expired - Fee Related
- 1999-06-02 TR TR2001/00348T patent/TR200100348T2/xx unknown
- 1999-06-02 BR BR9910877-1A patent/BR9910877A/pt not_active IP Right Cessation
- 1999-06-02 IL IL13993699A patent/IL139936A0/xx unknown
- 1999-06-02 EE EEP200000790A patent/EE200000790A/xx unknown
- 1999-06-02 TR TR2001/02985T patent/TR200102985T2/xx unknown
- 1999-06-02 CN CN99809287A patent/CN1311822A/zh active Pending
- 1999-06-02 JP JP2000551815A patent/JP2002516676A/ja active Pending
- 1999-06-02 AU AU41560/99A patent/AU770497B2/en not_active Expired - Fee Related
- 1999-06-02 HR HR20000832A patent/HRP20000832A2/hr not_active Application Discontinuation
- 1999-06-02 HU HU0103252A patent/HUP0103252A3/hu unknown
- 1999-06-02 CA CA002334171A patent/CA2334171A1/en not_active Abandoned
- 1999-06-02 YU YU75600A patent/YU75600A/sh unknown
- 1999-06-02 DK DK99925174T patent/DK1083934T3/da active
2000
- 2000-11-28 IS IS5742A patent/IS5742A/is unknown
- 2000-11-29 NO NO20006047A patent/NO20006047L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
WO1999062561A3 (en)	2000-08-03
TR200100348T2 (tr)	2001-07-23
DK1083934T3 (da)	2003-12-01
HK1034465A1 (en)	2001-10-26
AP2000001999A0 (en)	2000-12-31
DE69910202T2 (de)	2004-06-17
NO20006047L (no)	2001-02-01
HUP0103252A3 (en)	2003-09-29
CA2334171A1 (en)	1999-12-09
TR200102985T2 (tr)	2002-06-21
EP1281763A2 (de)	2003-02-05
EA200001124A1 (ru)	2001-08-27
YU75600A (sh)	2004-03-12
KR20010043968A (ko)	2001-05-25
EE200000790A (et)	2002-04-15
ID27483A (id)	2001-04-12
HRP20000832A2 (en)	2001-04-30
EP1083934A2 (de)	2001-03-21
PL345207A1 (en)	2001-12-03
NZ508505A (en)	2003-04-29
AU770497B2 (en)	2004-02-26
CN1311822A (zh)	2001-09-05
IS5742A (is)	2000-11-28
NO20006047D0 (no)	2000-11-29
HUP0103252A2 (hu)	2001-12-28
WO1999062561A2 (en)	1999-12-09
ATE246518T1 (de)	2003-08-15
ES2205830T3 (es)	2004-05-01
DE69910202D1 (de)	2003-09-11
BR9910877A (pt)	2002-01-22
EP1083934B1 (de)	2003-08-06
US6689758B1 (en)	2004-02-10
EP1281763A3 (de)	2003-07-09
AU4156099A (en)	1999-12-20
JP2002516676A (ja)	2002-06-11
PT1083934E (pt)	2003-12-31
IL139936A0 (en)	2002-02-10

Publication	Publication Date	Title
AU710386B2 (en)	1999-09-16	In vivo gene transfer methods for wound healing
SK18322000A3 (sk)	2001-11-06	Použitie molekuly nukleovej kyseliny, farmaceutický prostriedok s jej obsahom a molekula nukleovej kyseliny
AU764039B2 (en)	2003-08-07	Growth factor homolog ZVEGF3
AU763713B2 (en)	2003-07-31	Pharmaceutical uses of NAB1 and NAB2
CZ20004509A3 (cs)	2001-07-11	Způsob genové terapie
US20120100107A1 (en)	2012-04-26	In vivo transfer methods for wound healing
HK1034465B (en)	2004-01-30	Egr-1 for the manufacture of a medicament for treating wounds
HK1050914A (en)	2003-07-11	Early growth response-1 (egr-1) transcription factor
MXPA00011726A (en)	2001-11-21	Gene therapy method
ZA200006963B (en)	2002-01-02	Gene therapy method.
CZ2001142A3 (cs)	2001-06-13	Použití molekuly nukleové kyseliny
WO2001040460A1 (en)	2001-06-07	Screening method for compounds capable of modularing egr-1-regulated expression
Henry	2003	Biolistic augmentation of wound healing in diabetic and steroid treated rats
MXPA01000386A (en)	2001-11-21	Pharmaceutical uses of nab1 and nab2
ZA200100193B (en)	2002-01-08	Pharmaceutical uses of NAB1 and NAB2.
MXPA98008427A (es)	1999-09-01	Metodos de transferencia de genes in vivo para curacion de lesiones